MENLO PARK, Calif., July 19, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc., a growth-stage medical device company focused on the development and commercialization of proprietary devices that target the underlying causes of the world’s most prevalent eye diseases, today announced the closing of its initial public offering of 11,500,000 shares of common stock including the exercise in full of the underwriters’ option to purchase 1,500,000 additional shares of common stock, at the initial public offering price of $24.00 per share.